# Medicines and Healthcare products Regulatory Agency CERTIFICATE NUMBER : UK API 34369 Insp GMP 34369/18372677-0006 CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER(1).(2)

# Part 1

Issued following an inspection in accordance with : Regulation 331A of The Human Medicines Regulations 2012 (SI 2012/1916)

The competent authority of United Kingdom confirms the following :

The Manufacturer : ALMAC SCIENCES (SCOTLAND) LIMITED

Site address : ALMAC SCIENCES (SCOTLAND) LIMITED, 5 FLEMING BUILDING, EDINBURGH TECHNOPOLE, MILTON BRIDGE, PENICUIK, EH26 0BE, UNITED KINGDOM

Is an active substance manufacturer that has been inspected in accordance with Regulation 327 of The Human Medicines Regulations 2012 (SI 2012/1916).

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 27/02/2025, it is considered that it complies with

• The principles of GMP for active substances referred to in Regulation B17 and C17 of the Human Medicines Regulations 2012 (SI 2012/1916)

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in MHRA-GMDP. If it does not appear, please contact the issuing authority.

- (1) Guidance on the interpretation of this template can be found in the Help menu of MHRA-GMDP database.
- (2) These requirements fulfil the GMP recommendations of WHO.

## Part 2

### **Human Medicinal Products**

31

Manufacture of active substance. Names of substances subject to inspection :

• [1000018046] ACTIVE SUBSTANCES FOR CLINICAL TRIALS

### 3. MANUFACTURING OPERATIONS - ACTIVE SUBSTANCES

ACTIVE SUBSTANCES FOR CLINICAL TRIALS

Manufacture of Active Substance by Chemical Synthesis



	3.1.1 Manufacture Of Active Substance Intermediates
	3.1.2 Manufacture Of Crude Active Substance
	3.1.3 Salt Formation/Purification steps (eg. Crystallisation) Preparative chromatography
	3.1.4 Other Limited Active Substance pre-formulation
3.5	General Finishing Steps
	3.5.2 Primary Packaging
	3.5.3 Secondary Packaging
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
Any restric <mark>tions relat</mark> ed to the sc	cope of this certificate:

Building R	oom Line/equipment	QC Testing	Products	
		QC testing includes peptide APIs and IMPs containing those APIs.		
02/07/2025	Name and signature of the authorised person of the Competent Authority of United Kingdom			
	Confidential			
	Medicines and Healthcare products Regulatory Agency			
	Tel : Confidential			